We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type |
---|---|---|---|
AbbVie Inc | NYSE:ABBV | NYSE | Common Stock |
Price Change | % Change | Share Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|
2.98 | 1.85% | 163.79 | 164.25 | 160.74 | 161.85 | 5,850,104 | 01:00:00 |
By Colin Kellaher
AbbVie plans to advance its lutikizumab drug candidate into Phase 3 studies in the inflammatory skin disease hidradenitis suppurativa following a successful Phase 2 trial.
AbbVie on Monday said adults who had previously failed anti-TNF therapy and received lutikizumab in the Phase 2 study showed higher response rates in key primary and secondary endpoint measures of the disease than those treated with placebo.
The North Chicago, Ill., biopharmaceutical company said there is a significant unmet medical need in hidradenitis suppurativa, a chronic and often debilitating disease that can result in lumps, abscesses and scars under the arms, in the groin and in other areas of the body.
AbbVie is studying lutikizumab in several immune-mediated diseases, including hidradenitis suppurativa and ulcerative colitis. The company last year launched a Phase 3 study of its blockbuster immunology drug Rinvoq in hidradenitis suppurativa.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
January 08, 2024 09:01 ET (14:01 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year AbbVie Chart |
1 Month AbbVie Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions